Corcept Therapeutics Inc Sample Contracts

AutoNDA by SimpleDocs
INDEMNIFICATION AGREEMENT
Indemnification Agreement • November 14th, 2007 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware

AGREEMENT, made this day of , 20 , between Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and (the “Indemnitee”).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • March 31st, 2008 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 25, 2008, is by and between CORCEPT THERAPEUTICS INCORPORATED (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).

Corcept Therapeutics Incorporated 10,000,000 Shares Common Stock ($0.001 par value) Underwriting Agreement
Underwriting Agreement • January 21st, 2011 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York

Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom Stifel, Nicolaus & Company, Incorporated and Leerink Swann LLC are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares (the “ Firm Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 1,500,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.

EXHIBIT 4.2 CORCEPT THERAPEUTICS INCORPORATED AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENT
Information and Registration Rights Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
EXHIBIT 10.7 Corcept Therapeutics Incorporated PROMISSORY NOTE AND PLEDGE AGREEMENT
Note and Pledge Agreement • December 21st, 2001 • Corcept Therapeutics Inc • California
AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENT
Severance and Change in Control Agreement • March 31st, 2009 • Corcept Therapeutics Inc • Pharmaceutical preparations • California

THIS AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of September 19, 2008 (the “Effective Date”) is entered into by and between Joseph K. Belanoff, MD, Chief Executive Officer (“Executive”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).

COMMON STOCK PURCHASE AGREEMENT by and between KINGSBRIDGE CAPITAL LIMITED and CORCEPT THERAPEUTICS INCORPORATED dated as of March 25, 2008
Common Stock Purchase Agreement • March 31st, 2008 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York

This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 25th day of March, 2008, by and between Kingsbridge Capital Limited, an entity organized and existing under the laws of the British Virgin Islands, whose registered address is Palm Grove House, 2nd Floor, Road Town, Tortola, British Virgin Islands (the “Investor”) and Corcept Therapeutics Incorporated , a corporation organized and existing under the laws of the State of Delaware (the “Company”).

11,000,000 Shares CORCEPT THERAPEUTICS INCORPORATED Common Stock ($0.001 par value) UNDERWRITING AGREEMENT
Underwriting Agreement • July 6th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • March 29th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York

This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 29, 2012, by and among Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).

AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENT
Severance and Change in Control Agreement • March 31st, 2009 • Corcept Therapeutics Inc • Pharmaceutical preparations • California

THIS AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of September 19, 2008 (the “Effective Date”) is entered into by and between James N. Wilson, Chairman of the Board of Directors (“Executive”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).

MASTER SERVICES AGREEMENT
Master Services Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations

This Master Service Agreement (the “Agreement”), made this 17th day of January, 2003 (the “Effective Date”), by and between PPD Development, LP, a Texas limited partnership, with its principal executive offices located at 3151 South 17th Street, Wilmington, North Carolina 28412 (“PPD”) and Corcept with its principal executive offices located at 275 Middlefield Road, Suite A, Menlo Park, California 94025 (“Sponsor”).

MASTER
Clinical Development Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
SEVERANCE AND CHANGE IN CONTROL AGREEMENT
Severance and Change in Control Agreement • March 1st, 2021 • Corcept Therapeutics Inc • Pharmaceutical preparations • California

THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of March 1, 2021 (the “Effective Date”) is entered into by and between Atabak Mokari, Chief Financial Officer (“CFO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).

SEVERANCE AND CHANGE IN CONTROL AGREEMENT
Severance and Change in Control Agreement • May 9th, 2019 • Corcept Therapeutics Inc • Pharmaceutical preparations • California

THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of March 18, 2019 (the “Effective Date”) is entered into by and between Andreas Grauer, M.D., Chief Medical Officer (“CMO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).

September 5, 2012 Manufacturing and Supply Agreement
Corcept Therapeutics Inc • May 12th, 2014 • Pharmaceutical preparations • Delaware

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

Corcept Therapeutics Incorporated
Corcept Therapeutics Inc • March 14th, 2014 • Pharmaceutical preparations

On behalf of Corcept Therapeutics Inc. (“Corcept”), I propose amending the Manufacturing and Supply Agreement between Corcept and PCAS dated November 3, 2006 (the “Agreement”) as follows:

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 2 TO...
Distribution Services Agreement • November 3rd, 2022 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware

This Amendment No. 2 to Distribution Services Agreement (this “Amendment”), effective as of September 16, 2022 (the “Amendment Effective Date”), is made by and between Corcept Therapeutics Incorporated, having its principal place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Corcept”) and Optime Care, Inc., having its principal place of business at 4060 Wedgeway Court, Earth City, MO 63045 (“Optime”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Agreement (as defined below).

Manufacturing and Supply Agreement
And Supply Agreement • May 10th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

AutoNDA by SimpleDocs
FIFTH AMENDMENT
Corcept Therapeutics Inc • August 4th, 2020 • Pharmaceutical preparations

THIS FIFTH AMENDMENT (the "Fifth Amendment") is made and entered into as of June 17, 2020 by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation ("Tenant").

Corcept Therapeutics Incorporated
Corcept Therapeutics Inc • March 15th, 2013 • Pharmaceutical preparations

On behalf of Corcept Therapeutics Inc. (“Corcept”), I propose amending the Manufacturing and Supply Agreement between Corcept and PCAS dated November 3, 2006 (the “Agreement”) as follows:

COMMERCIAL OUTSOURCING SERVICES AGREEMENT
Commercial Outsourcing Services Agreement • August 9th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • Texas

This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of April 14, 2011 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and Corcept Therapeutics, INC., a Delaware corporation (the “Company”).

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT TO DISTRIBUTION...
Distribution Services Agreement • November 3rd, 2022 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware

This Amendment to Distribution Services Agreement (this “Amendment”), effective as of August 1, 2022 (the “Amendment Effective Date”), is made by and between Corcept Therapeutics Incorporated, having its principal place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Corcept”) and Optime Care, Inc., having its principal place of business at 4060 Wedgeway Court, Earth City, MO 63045 (“Optime”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Agreement (as defined below).

COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • August 8th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware

THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 7th day of April, 2014 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Corcept Therapeutics Incorporated, having a place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.

Corcept Therapeutics Incorporated
Corcept Therapeutics Inc • August 9th, 2013 • Pharmaceutical preparations

This letter describes our agreement regarding your retirement from Corcept, which will take place on December 31, 2013 (the “retirement date”). Until the retirement date, you will continue to serve as our President and Secretary and as a member of Corcept’s Executive Committee at your current salary and benefits, including paid vacation days and access to your current office (together, your “compensation”). Your compensation will remain the same until the retirement date, even if we reduce the scope and scale of your responsibilities or terminate you (unless we terminate you for cause).

COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • October 22nd, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware

THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 7th day of April, 2014 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Corcept Therapeutics Incorporated, having a place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.

SECOND AMENDMENT
Corcept Therapeutics Inc • February 24th, 2020 • Pharmaceutical preparations

THIS SECOND AMENDMENT (the “Second Amendment”) is made and entered into as of March 12, 2018 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”).

Shares CORCEPT THERAPEUTICS INCORPORATED COMMON STOCK UNDERWRITING AGREEMENT Dated
Underwriting Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York

Introduction. Corcept Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”), and a stockholder of the Company (the “Selling Stockholder”) named in Schedule B hereto severally propose to sell to the several Underwriters, an aggregate of shares of the common stock, par value $.001 per share, of the Company (the “Firm Shares”), of which shares are to be issued and sold by the Company and shares are to be sold by the Selling Stockholder, with such Selling Stockholder selling the number of shares set forth in Schedule B hereto.

SECOND AMENDMENT
Second Amendment • November 14th, 2008 • Corcept Therapeutics Inc • Pharmaceutical preparations

THIS SECOND AMENDMENT (the “Amendment”) is made and entered into as of October 17th, 2008 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”).

Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry
Corcept Therapeutics Inc • July 25th, 2007 • Pharmaceutical preparations

MENLO PARK, CA -- 07/25/2007 -- Corcept Therapeutics (NASDAQ: CORT) and Xceleron today announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator Mass Spectrometry (AMS) technology.

SEVENTH AMENDMENT TO LEASE
Lease • May 5th, 2022 • Corcept Therapeutics Inc • Pharmaceutical preparations

THIS SEVENTH AMENDMENT TO LEASE (the "Seventh Amendment") is made and entered into as of March 18, 2022 by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”).

MANUFACTURING AND SUPPLY AGREEMENT
Manufacturing and Supply Agreement • May 10th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • California

[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Time is Money Join Law Insider Premium to draft better contracts faster.